R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
News Vedanta's microbiome therapy for IBD disappoints Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.
News EnteroBiotix cues up larger trial of microbiome IBS therapy EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microbiome species.
News Nestle bids to take control of Seres’ C diff drug Vowst Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg
R&D Reuters Pharma USA 2024 – Moreno Perugini Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.
R&D Why gut bacteria is the next frontier in medicine Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
